| Literature DB >> 29049309 |
Abstract
Prevalence of metabolic syndrome (MetS) in children is increasing and identifying the risk factors for MetS during childhood is an important first step to prevent chronic diseases later in life. The aim of the present study was to evaluate the prevalence of MetS and cardiometabolic risk factor (CMRF) clustering among Korean children and adolescents and to validate the associated anthropometric and laboratory surrogate markers. We used data from the 2011-2014 Korean National Health and Nutrition Examination Survey. In total, data for 2,935 subjects (1539 boys, 52.6%) aged 10-19 years were assessed. MetS was defined by central obesity plus any two or more of CMRFs such as abdominal obesity, hypertension, hyperglycemia, hypertriglyceridemia, and decreased high density lipoprotein cholesterol (HDL-C) using the International Diabetes Federation criteria for children and adolescents. The presence of two or more CMRFs was classified as CMRF clustering. The prevalence of MetS and CMRF clustering in this group was found to be 1.8% and 8.9%, respectively. The receiver operating characteristic analysis of MetS and CMRF clustering, and the area under the curve (95% confidence interval) of surrogate markers revealed that the waist circumference to height ratio [0.960 (95% CI 0.959-0.960), cut-off 0.491] showed the highest predictability for MetS whereas triglyceride to HDL-C ratio [0.891 (95% CI 0.891-0.892), cut-off 2.63] showed the highest predictability for CMRF clustering. Long-term follow-up is needed for further validation.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29049309 PMCID: PMC5648147 DOI: 10.1371/journal.pone.0186050
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Anthropometric, clinical, and biochemical characteristics in study participants.
| Total (n = 2935, 100%) | Boys (n = 1539, 52.6%) | Girls (n = 1396, 47.4%) | ||
|---|---|---|---|---|
| Estimated population | 5,191,866 | 2,728,574 | 2,463,292 | - |
| Age (years) | 14.8 ± 0.1 | 14.8 ± 0.1 | 14.9 ± 0.1 | 0.265 |
| Height (cm) | 162.4 ± 0.2 | 166.3 ± 0.4 | 158.1 ± 0.2 | <0.001 |
| Height z-score | 0.35 ± 0.03 | 0.41 ± 0.03 | 0.28 ± 0.04 | 0.003 |
| Weight (kg) | 55.9 ± 0.3 | 59.6 ± 0.5 | 51.9 ± 0.4 | <0.001 |
| Weight z-score | 0.18 ± 0.03 | 0.20 ± 0.04 | 0.16 ± 0.04 | 0.343 |
| Body mass index (kg/m2) | 20.9 ± 0.1 | 21.2 ± 0.1 | 20.6 ± 0.1 | <0.001 |
| BMI z-score | 0.02 ± 0.03 | 0.01 ± 0.04 | 0.04 ± 0.04 | 0.571 |
| BMI classification | ||||
| Normal (%) | 2210 (74.1%) | 1114 (70.7%) | 1096 (77.8%) | 0.001 |
| Overweight (%) | 380 (13.1%) | 211 (14.3%) | 169 (11.9%) | |
| Obese (%) | 345 (12.8%) | 214 (15.0%) | 131 (10.3%) | |
| Waist circumference (cm) | 70.2 ± 0.2 | 72.2 ± 0.3 | 67.9 ± 0.3 | <0.001 |
| Waist circumference to height ratio | 0.432 ± 0.001 | 0.434 ± 0.002 | 0.429 ± 0.002 | 0.041 |
| Systolic blood pressure (mm Hg) | 107.6 ± 0.2 | 110.0 ± 0.3 | 104.9 ± 0.3 | <0.001 |
| Diastolic blood pressure (mm Hg) | 66.5 ± 0.2 | 66.9 ± 0.3 | 66.0 ± 0.3 | 0.019 |
| Total cholesterol (mg/dL) | 156.3 ± 0.7 | 151.5 ± 0.9 | 161.8 ± 0.9 | <0.001 |
| Triglyceride (mg/dL) | 73.8 ± 0.9 | 73.1 ± 1.2 | 74.6 ± 1.3 | 0.358 |
| HDL-C (mg/dL) | 49.4 ± 0.3 | 47.6 ± 0.3 | 51.4 ± 0.4 | <0.001 |
| Non-HDL-C (mg/dL) | 105.1 ± 0.7 | 102.4 ± 0.9 | 108.3 ± 0.9 | <0.001 |
| Triglyceride/HDL-C ratio | 1.48 ± 0.03 | 1.51 ± 0.03 | 1.45 ± 0.03 | 0.186 |
| Fasting glucose (mmol/L) | 4.99 ± 0.01 | 5.01 ± 0.01 | 4.96 ± 0.02 | 0.042 |
| HbA1c (%) | 5.45 ± 0.01 | 5.46 ± 0.01 | 5.45 ± 0.01 | 0.441 |
| Serum AST (IU/L) | 18.6 ± 0.2 | 20.3 ± 0.2 | 16.8 ± 0.2 | <0.001 |
| Serum ALT (IU/L) | 15.1 ± 0.3 | 18.1 ± 0.5 | 11.7 ± 0.2 | <0.001 |
| Metabolic syndrome (%) | 31 (1.8%) | 18 (1.9%) | 13 (1.7%) | 0.765 |
| CMRF clustering (%) | 188 (8.9%) | 109 (9.4%) | 79 (8.2%) | 0.407 |
| Abdominal obesity (%) | 243 (9.1%) | 119 (8.2%) | 124 (10.2%) | 0.109 |
| Hypertension (%) | 92 (3.6%) | 70 (5.6%) | 22 (1.5%) | <0.001 |
| Hyperglycemia (%) | 207 (7.0%) | 128 (8.2%) | 79 (5.6%) | 0.015 |
| Hypertriglyceridemia (%) | 229 (8.6%) | 133 (9.3%) | 96 (7.9%) | 0.254 |
| Low HDL-C (%) | 389 (18.2%) | 207 (17.7%) | 182 (18.7%) | 0.614 |
| Elevated ALT (%) | 146 (5.1%) | 102 (7.0%) | 44 (3.1%) | <0.001 |
BMI: body mass index; HDL-C: high density lipoprotein cholesterol; aspartate transaminase; HbA1c: glycated hemoglobin; ALT: alanine transaminase; CMRF: cardio metabolic risk factor.
Data were expressed as weight mean ± standard error or number of cases (weighted percent).
Total cholesterol, triglyceride, HDL-C, non-HDL cholesterol and TG/HDL-C ratio were log-transformed and expressed as geometric mean ± standard error.
Age- and sex-adjusted odds ratios (95% confidence intervals) of surrogate markers predicting metabolic syndrome and cardiometabolic risk factor (CMRF) clustering.
| Category | Surrogate markers | Total | 10–15 years | 16–19 years | Boys | Girls |
|---|---|---|---|---|---|---|
| Metabolic syndrome | HbA1c (%) | 1.8 (1.3–2.6) | 1.8 (1.3–2.7) | 1.7 (0.9–3.3) | 3.88 (0.91–16.4) | 1.59 (1.08–2.35) |
| TG/HDL-C ratio | 2.3 (1.8–3.0) | 1.9 (1.3–2.8) | 3.1 (2.1–4.5) | 2.11 (1.31–3.39) | 2.56 (2.00–3.28) | |
| Non-HDL-C (mg/dL) | 1.04 (1.03–1.05) | 1.03 (1.02–1.05) | 1.04 (1.03–1.06) | 1.03 (1.02–1.05) | 1.05 (1.03–1.06) | |
| ALT (IU/L) | 1.03 (1.02–1.05) | 1.03 (1.02–1.04) | 1.05 (1.03–1.07) | 1.03 (1.02–1.04) | 1.06 (1.03–1.10) | |
| WHtR (%) | 1.4 (1.3–1.5) | 1.4 (1.3–1.5) | 1.4 (1.3–1.5) | 1.37 (1.28–1.46) | 1.48 (1.35–1.62) | |
| BMI z-score | 11.4 (7.3–17.8) | 13.5 (6.7–27.2) | 10.5 (5.6–19.7) | 15.4 (7.1–33.3) | 8.9 (5.1–15.6) | |
| CMRF clustering | HbA1c (%) | 2.1 (1.1–4.0) | 2.0 (0.9–4.7) | 2.0 (0.8–5.2) | 3.7 (1.7, 7.9) | 1.7 (1.0–3.0) |
| TG/HDL-C ratio | 3.9 (3.3–4.6) | 4.2 (3.4–5.3) | 4.1 (3.1–5.3) | 3.7 (3.0–4.5) | 4.6 (3.4–6.1) | |
| Non-HDL-C (mg/dL) | 1.03 (1.03–1.04) | 1.04 (1.03–1.04) | 1.03 (1.02–1.04) | 1.03 (1.02–1.04) | 1.03 (1.02–1.04) | |
| ALT (IU/L) | 1.05 (1.03–1.06) | 1.05 (1.02–1.07) | 1.05 (1.04–1.06) | 1.04 (1.03–1.05) | 1.06 (1.02–1.11) | |
| WHtR (%) | 1.3 (1.3–1.4) | 1.3 (1.2–1.4) | 1.3 (1.2–1.4) | 1.3 (1.2–1.4) | 1.3 (1.3–1.4) | |
| BMI z-score | 4.1 (3.2–5.2) | 4.7 (3.4–6.5) | 3.6 (2.6–5.1) | 4.6 (3.1–6.9) | 3.6 (2.6–4.9) |
*P <0.05,
**P <0.01
HbA1c: glycated hemoglobin; TG/HDL-C: triglyceride to high density lipoprotein cholesterol; ALT: alanine transaminase; WHtR: Waist circumference to height ratio; BMI: Body mass index.
Area under the curve (95% confidence intervals) and cut-off values of surrogate markers for predicting metabolic syndrome and cardiometabolic risk factor (CMRF) clustering.
| Category | Surrogate markers | Total | 10–15 years | 16–19 years | Boys | Girls | Cut-off value | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome (IDF) | HbA1c (%) | 0.627 (0.625, 0.629) | 0.637 (0.635, 0.639) | 0.624 (0.621, 0.627) | 0.621 (0.618, 0.623) | 0.633 (0.630, 0.636) | 5.5 | 70.5 | 50.5 |
| TG/HDL-C ratio | 0.947 (0.946, 0.948) | 0.965 (0.964, 0.965) | 0.936 (0.934, 0.937) | 0.934 (0.932, 0.935) | 0.963 (0.962, 0.964) | 2.64 | 95.1 | 86.4 | |
| Non-HDL-C (mg/dL) | 0.779 (0.778, 0.781) | 0.747 (0.745, 0.749) | 0.808 (0.806, 0.810) | 0.735 (0.733, 0.737) | 0.844 (0.842, 0.845) | 111.6 | 81.3 | 63.7 | |
| ALT (IU/L) | 0.820 (0.819, 0.822) | 0.816 (0.814, 0.818) | 0.822 (0.820 0.823) | 0.867 (0.865, 0.868) | 0.811 (0.809, 0.813) | 21 | 63.5 | 88.2 | |
| WHtR | 0.960 (0.959, 0.960) | 0.954 (0.953, 0.954) | 0.964 (0.963, 0.964) | 0.967 (0.967, 0.968) | 0.957 (0.957, 0.957) | 0.491 | 96.5 | 88.2 | |
| BMI z-score | 0.959 (0.957, 0.962) | 0.957 (0.956, 0.957) | 0.962 (0.961, 0.962) | 0.966 (0.966, 0.966) | 0.955 (0.954, 0.955) | 1.35 | 95.1 | 89.4 | |
| CMRF clustering | HbA1c (%) | 0.607 (0.606, 0.608) | 0.596 (0.594, 0.597) | 0.628 (0.627, 0.629) | 0.580 (0.578, 0.581) | 0.636 (0.634, 0.637) | 5.6 | 50.0 | 66.8 |
| TG/HDL-C ratio | 0.891 (0.891, 0.892) | 0.917 (0.916, 0.918) | 0.869 (0.868, 0.869) | 0.898 (0.898, 0.899) | 0.885 (0.884, 0.885) | 2.63 | 74.4 | 90.5 | |
| Non-HDL-C (mg/dL) | 0.720 (0.719, 0.721) | 0.716 (0.715, 0.717) | 0.725 (0.724, 0.726) | 0.708 (0.707, 0.709) | 0.738 (0.737, 0.739) | 118.7 | 60.1 | 75.2 | |
| ALT (IU/L) | 0.730 (0.729, 0.730) | 0.780 (0.779, 0.781) | 0.686 (0.685, 0.687) | 0.798 (0.797, 0.799) | 0.704 (0.702, 0.705) | 15 | 61.8 | 74.4 | |
| WHtR | 0.842 (0.841, 0.843) | 0.843 (0.842, 0.844) | 0.840 (0.839, 0.841) | 0.857 (0.856, 0.858) | 0.829 (0.828, 0.830) | 0.469 | 74.1 | 82.9 | |
| BMI z-score | 0.829 (0.828, 0.830) | 0.839 (0.838, 0.840) | 0.821 (0.820, 0.822) | 0.853 (0.852, 0.854) | 0.804 (0.803, 0.805) | 1.06 | 68.2 | 87.2 |
All P values were <0.001 when compared AUC between age groups and sex.
HbA1c: glycated hemoglobin; TG/HDL-C: triglyceride to high density lipoprotein cholesterol; ALT: alanine transaminase; WHtR: waist circumference to height ratio; BMI: body mass index.